EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of Underlying Portal Hypertension on Severity and Course of Acute‐On‐Chronic Liver Failure

Vlad Taru iD, Georg Kramer iD, Benedikt S Hofer iD, Nina Dominik iD, Lorenz Balcar iD, Mathias Schneeweiss-Gleixner, Bogdan Procopet iD, Michael Trauner, Mattias Mandorfer iD, Philipp Schwabl, Thomas Reiberger iD, Benedikt Simbrunner iD

Liver International · 2025

DOI: 10.1111/liv.70363 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International, 2025. Verfasst von Vlad Taru und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Acute-On-Chronic Liver Failure, Hypertension, Portal. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Christian Doppler Forschungsgesellschaft, Ludwig Boltzmann Gesellschaft, Romanian Ministry of Research Innovation and Digitalisation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims The impact of portal hypertension (PH) during acute‐on‐chronic liver failure (ACLF) remains unclear. This study investigated the link between underlying PH severity, systemic inflammation (SI), and the course of ACLF.

Methods

Consecutive patients with ACLF ( n = 192) who met the EASL‐CLIF criteria were retrospectively included. PH severity (hepatic venous pressure gradient, HVPG; platelet count, PLT; and other clinical/radiologic PH surrogates) and SI (white blood cell count; C‐reactive protein [CRP], interleukin‐6) were assessed at the last pre‐ACLF visit, ACLF diagnosis (D0), and after 7 (D7), 28 (D28), and 90 (D90) days.

Results

All patients had clinical/radiological signs of PH, and 91 (47%) patients developed ACLF grade 1, 62 (32%) ACLF‐2, and 39 (21%) ACLF‐3. Patients with different D0‐ACLF grades showed similar SI biomarker levels pre‐ACLF, whereas these increased significantly during ACLF. Median PLT decreased in parallel with the ACLF grade and from D0 (ACLF‐3:72; vs. ACLF‐2:81; vs. ACLF‐1:91 G/L; p = 0.094) to D7 (ACLF‐3:39 vs. ACLF‐2:64; vs. ACLF‐1:89 G/L; p < 0.001). In multivariable Cox regression models, D0‐PLT (aHR: 0.96 per 10 G/L [95% CI: 0.93–0.99], p = 0.015) independently predicted D28 mortality. A logistic regression model including sex, D0‐PLT, D0‐CRP, and CLIF‐C ACLF score predicted D28 mortality (AUROC: 0.79 [0.73–0.86]; p < 0.001) and outperformed ( p = 0.036) the MELD‐Na score (AUROC: 0.71 [0.63–0.78]; p < 0.001).

Conclusions

Although PH is a necessary condition for ACLF development, underlying PH severity does not confer a risk for higher ACLF severity but impacts survival after ACLF resolution. PLT emerged as a predictor of D28 mortality, independent of the CLIF‐C ACLF score.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute-On-Chronic Liver FailureHypertension, PortalHumansMaleFemaleMiddle AgedRetrospective StudiesSeverity of Illness IndexAgedPlatelet CountBiomarkersAdultC-Reactive ProteinInterleukin-6InflammationLeukocyte Count

Stichwörter der Autor:innen

acute decompensationcirrhosishepatic venous pressure gradientplateletportal hypertensionsystemic inflammation

Substanzen

BiomarkersC-Reactive ProteinInterleukin-6

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
  • Vienna Hepatic Hemodynamic Lab, Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
  • Iuliu Hatieganu University of Medicine and Pharmacy, 4th Dept. of Internal Medicine and "Octavian Fodor" Regional Institute of Gastroenterology and Hepatology, Hepatology Department, Cluj-Napoca, Romania.
  • Christian-Doppler Laboratory for Portal Hypertension and Liver Fibrosis, Medical University of Vienna, Vienna, Austria.
  • Clinical Research Group MOTION, Medical University of Vienna, Vienna, Austria.
  • CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.

ORCID-Profile: Vlad Taru, Georg Kramer, Benedikt S Hofer, Nina Dominik, Lorenz Balcar, Bogdan Procopet, Mattias Mandorfer, Thomas Reiberger, Benedikt Simbrunner

Förderung

  • Christian Doppler Forschungsgesellschaft
  • Ludwig Boltzmann Gesellschaft
  • Romanian Ministry of Research Innovation and Digitalisation

Zitieren

APA

Taru, V., Kramer, G., Hofer, B. S., Dominik, N., Balcar, L., Schneeweiss-Gleixner, M., Procopet, B., Trauner, M., Mandorfer, M., Schwabl, P., Reiberger, T., & Simbrunner, B. (2025). Impact of Underlying Portal Hypertension on Severity and Course of Acute‐On‐Chronic Liver Failure. Liver International. https://doi.org/10.1111/liv.70363

Vancouver

Taru V, Kramer G, Hofer BS, Dominik N, Balcar L, Schneeweiss-Gleixner M, et al. Impact of Underlying Portal Hypertension on Severity and Course of Acute‐On‐Chronic Liver Failure. Liver International. 2025. doi:10.1111/liv.70363

BibTeX
@article{Taru2025,
  author = {Taru, Vlad and Kramer, Georg and Hofer, Benedikt S and Dominik, Nina and Balcar, Lorenz and Schneeweiss-Gleixner, Mathias and Procopet, Bogdan and Trauner, Michael and Mandorfer, Mattias and Schwabl, Philipp and Reiberger, Thomas and Simbrunner, Benedikt},
  title = {Impact of Underlying Portal Hypertension on Severity and Course of Acute‐On‐Chronic Liver Failure},
  journal = {Liver International},
  year = {2025},
  doi = {10.1111/liv.70363}
}
Kostenlos starten →